-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of the State Food and Drug Administration showed that Shandong Qidu Pharmaceutical/Shandong Yumankun Biopharmaceutical Co.
, Ltd.
was approved for production of piracetam injection, which was reported to be a Class 3 imitation, and was deemed to have been over-evaluated
.
According to data from Minet.
com, the market size of the terminal piracetam injection in China's public medical institutions in 2020 is close to 2 billion yuan, a year-on-year increase of 37.
33%
.
, Ltd.
was approved for production of piracetam injection, which was reported to be a Class 3 imitation, and was deemed to have been over-evaluated
.
According to data from Minet.
com, the market size of the terminal piracetam injection in China's public medical institutions in 2020 is close to 2 billion yuan, a year-on-year increase of 37.
33%
.
Piracetam is a cyclic derivative of γ-aminobutyric acid.
It is a drug for improving brain metabolism.
It has the effect of resisting brain function damage caused by physical and chemical factors.
It is clinically used for acute and chronic cerebrovascular diseases, brain trauma, various It is used to treat memory loss and mild and moderate brain dysfunction caused by various reasons such as toxic encephalopathy, and it is also used for children with intellectual developmental delay
.
It is a drug for improving brain metabolism.
It has the effect of resisting brain function damage caused by physical and chemical factors.
It is clinically used for acute and chronic cerebrovascular diseases, brain trauma, various It is used to treat memory loss and mild and moderate brain dysfunction caused by various reasons such as toxic encephalopathy, and it is also used for children with intellectual developmental delay
.
At present, the main dosage forms of piracetam that have been marketed in China include injections, tablets, granules, etc.
, among which injections are the main form
.
According to data from Minet.
com, in 2020, the sales of terminal piracetam injections in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 2 billion yuan, a year-on-year increase of 37.
33%.
In the first half of the year, the sales growth rate reached 46.
75%
.
, among which injections are the main form
.
According to data from Minet.
com, in 2020, the sales of terminal piracetam injections in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 2 billion yuan, a year-on-year increase of 37.
33%.
In the first half of the year, the sales growth rate reached 46.
75%
.
Sales of terminal piracetam injections in Chinese public medical institutions (unit: 10,000 yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Application of Consistency Evaluation of Piracetam Injection
Source: Minet Consistency Evaluation Database
4 pharmaceutical companies submitted piracetam injection marketing applications under the new registration category, among which Shandong Qidu Pharmaceutical/Shandong Yumankun Bio's products have been approved for production and deemed to have been reviewed, which is the first in China; 2 pharmaceutical companies The company has submitted a supplementary application for the consistency evaluation of the product, which is still under review and approval
.
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
A few days ago, the official website of the State Food and Drug Administration showed that Shandong Qidu Pharmaceutical/Shandong Yumankun Biopharmaceutical Co.
, Ltd.
was approved for production of piracetam injection, which was reported to be a Class 3 imitation, and was deemed to have been over-evaluated
.
According to data from Minet.
com, the market size of the terminal piracetam injection in China's public medical institutions in 2020 is close to 2 billion yuan, a year-on-year increase of 37.
33%
.
, Ltd.
was approved for production of piracetam injection, which was reported to be a Class 3 imitation, and was deemed to have been over-evaluated
.
According to data from Minet.
com, the market size of the terminal piracetam injection in China's public medical institutions in 2020 is close to 2 billion yuan, a year-on-year increase of 37.
33%
.
Piracetam is a cyclic derivative of γ-aminobutyric acid.
It is a drug for improving brain metabolism.
It has the effect of resisting brain function damage caused by physical and chemical factors.
It is clinically used for acute and chronic cerebrovascular diseases, brain trauma, various It is used to treat memory loss and mild and moderate brain dysfunction caused by various reasons such as toxic encephalopathy, and it is also used for children with intellectual developmental delay
.
It is a drug for improving brain metabolism.
It has the effect of resisting brain function damage caused by physical and chemical factors.
It is clinically used for acute and chronic cerebrovascular diseases, brain trauma, various It is used to treat memory loss and mild and moderate brain dysfunction caused by various reasons such as toxic encephalopathy, and it is also used for children with intellectual developmental delay
.
At present, the main dosage forms of piracetam that have been marketed in China include injections, tablets, granules, etc.
, among which injections are the main form
.
According to data from Minet.
com, in 2020, the sales of terminal piracetam injections in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 2 billion yuan, a year-on-year increase of 37.
33%.
In the first half of the year, the sales growth rate reached 46.
75%
.
, among which injections are the main form
.
According to data from Minet.
com, in 2020, the sales of terminal piracetam injections in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 2 billion yuan, a year-on-year increase of 37.
33%.
In the first half of the year, the sales growth rate reached 46.
75%
.
Sales of terminal piracetam injections in Chinese public medical institutions (unit: 10,000 yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Application of Consistency Evaluation of Piracetam Injection
Source: Minet Consistency Evaluation Database
4 pharmaceutical companies submitted piracetam injection marketing applications under the new registration category, among which Shandong Qidu Pharmaceutical/Shandong Yumankun Bio's products have been approved for production and deemed to have been reviewed, which is the first in China; 2 pharmaceutical companies The company has submitted a supplementary application for the consistency evaluation of the product, which is still under review and approval
.
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
A few days ago, the official website of the State Food and Drug Administration showed that Shandong Qidu Pharmaceutical/Shandong Yumankun Biopharmaceutical Co.
, Ltd.
was approved for production of piracetam injection, which was reported to be a Class 3 imitation, and was deemed to have been over-evaluated
.
According to data from Minet.
com, the market size of the terminal piracetam injection in China's public medical institutions in 2020 is close to 2 billion yuan, a year-on-year increase of 37.
33%
.
, Ltd.
was approved for production of piracetam injection, which was reported to be a Class 3 imitation, and was deemed to have been over-evaluated
.
According to data from Minet.
com, the market size of the terminal piracetam injection in China's public medical institutions in 2020 is close to 2 billion yuan, a year-on-year increase of 37.
33%
.
Piracetam is a cyclic derivative of γ-aminobutyric acid.
It is a drug for improving brain metabolism.
It has the effect of resisting brain function damage caused by physical and chemical factors.
It is clinically used for acute and chronic cerebrovascular diseases, brain trauma, various It is used to treat memory loss and mild and moderate brain dysfunction caused by various reasons such as toxic encephalopathy, and it is also used for children with intellectual developmental delay
.
children children childrenIt is a drug for improving brain metabolism.
It has the effect of resisting brain function damage caused by physical and chemical factors.
It is clinically used for acute and chronic cerebrovascular diseases, brain trauma, various It is used to treat memory loss and mild and moderate brain dysfunction caused by various reasons such as toxic encephalopathy, and it is also used for children with intellectual developmental delay
.
At present, the main dosage forms of piracetam that have been marketed in China include injections, tablets, granules, etc.
, among which injections are the main form
.
According to data from Minet.
com, in 2020, the sales of terminal piracetam injections in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 2 billion yuan, a year-on-year increase of 37.
33%.
In the first half of the year, the sales growth rate reached 46.
75%
.
hospital hospital hospital, among which injections are the main form
.
According to data from Minet.
com, in 2020, the sales of terminal piracetam injections in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 2 billion yuan, a year-on-year increase of 37.
33%.
In the first half of the year, the sales growth rate reached 46.
75%
.
Sales of terminal piracetam injections in Chinese public medical institutions (unit: 10,000 yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Application of Consistency Evaluation of Piracetam Injection
Source: Minet Consistency Evaluation Database
4 pharmaceutical companies submitted piracetam injection marketing applications under the new registration category, among which Shandong Qidu Pharmaceutical/Shandong Yumankun Bio's products have been approved for production and deemed to have been reviewed, which is the first in China; 2 pharmaceutical companies The company has submitted a supplementary application for the consistency evaluation of the product, which is still under review and approval
.
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
